Comparison · NCT01560624-deaths
UT-15C vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. UT-15C vs Placebo: deaths from any cause. Trial comparisons, record NCT01560624-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01560624-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0491 | 0.0309 | 0.0773 | wilson | |
| Risk in group 2 | 0.0523 | 0.0334 | 0.0812 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00319 | -0.0373 | 0.0307 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.939 | 0.492 | 1.79 | log | |
| Odds ratio, group 1 over group 2 | 0.936 | 0.474 | 1.85 | log | |
| Number needed to treat, for one fewer death from any cause on UT-15C than on Placebo | 313 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | UT-15C | Treprostinil diolamine extended-release tablets (oral) 0.125 to 12 mg TID~Treprostinil Diolamine: Active | 17 | 346 | EG000 |
| Group 2 | Placebo | Matching placebo tablets (oral)~Placebo: Placebo | 18 | 344 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- The study lasted 6 years; however, subjects remained in the study for various durations. The longest subject duration in the study was 5.1 years.
Source ClinicalTrials.gov
Trial
- Title
- Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
- NCT number
- NCT01560624
- Phases
- PHASE3
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil Diolamine, Placebo
- Lead sponsor
- United Therapeutics
- Results first posted
- 2020-02-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01560624?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01560624-deaths